-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in IgA Nephropathy (Berger's Disease) Drug Details: HRS-5965 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XHS-003 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XHS-003 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XHS-003 in IgA Nephropathy (Berger's Disease) Drug Details: XHS-003 is...
-
Product Insights
IgA Nephropathy (Berger’s Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
IgA Nephropathy Clinical Trial Report Overview A total of 298 IgA Nephropathy clinical trials were conducted as of January 2024. The IgA Nephropathy clinical trial report provides a comprehensive understanding of the IgA Nephropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADX-097 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADX-097 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADX-097 in Inflammation Drug Details: ADX-097 is under development for the treatment...
-
Product Insights
NewComplement C3 – Drugs In Development, 2024
The Complement C3 pipeline drugs market research report outlays comprehensive information on the Complement C3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Ophthalmology, Genito Urinary System, and Central Nervous System which include indications of Autoimmune Disorders, Inflammation, Geographic Atrophy, Dry (Atrophic) Macular Degeneration, Glomerulonephritis, IgA Nephropathy (Berger's Disease), Unspecified Neurologic Disorders, and Neuromyelitis Optica (Devic's...
-
Product Insights
NewMannan Binding Lectin Serine Protease 2 – Drugs In Development, 2024
The Mannan Binding Lectin Serine Protease 2 pipeline drugs market research report outlays comprehensive information on the Mannan Binding Lectin Serine Protease 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Genito Urinary System, Immunology, Cardiovascular, and Central Nervous System which include indications of IgA Nephropathy (Berger's Disease), Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Lupus Nephritis,...
-
Product Insights
NewComplement Factor B – Drugs In Development, 2024
The Complement Factor B pipeline drugs market research report outlays comprehensive information on the Complement Factor B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Genito Urinary System, Ophthalmology, and Hematological Disorders which include indications of Unspecified Immunological Disorders, Lupus Nephritis, IgA Nephropathy (Berger's Disease), Glomerulonephritis, Geographic Atrophy, Ocular Inflammation, Paroxysmal Nocturnal Hemoglobinuria, and Acquired (Autoimmune)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Lupus Nephritis Drug Details: Povetacicept is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Membranous Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Membranous Glomerulonephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Membranous Glomerulonephritis Drug Details: Povetacicept is under development for...
-
Product Insights
NewTumor Necrosis Factor Receptor Superfamily Member 13C – Drugs In Development, 2024
The Tumor Necrosis Factor Receptor Superfamily Member 13C pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 13C targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Genito Urinary System, and Hematological Disorders which include indications of Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Systemic Lupus Erythematosus, Lupus Nephritis, IgA...